SCYX - SCYNEXIS, Inc.
| Previous Close | 1.3700 |
| Open | 1.3900 |
| Bid | 1.35 x 3000 |
| Ask | 1.45 x 900 |
| Day's Range | 1.3400 - 1.4000 |
| 52 Week Range | 0.3500 - 2.1500 |
| Volume | 494,259 |
| Avg. Volume | 1,208,755 |
| Market Cap | 66.201M |
| Beta (3Y Monthly) | 3.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.81 |
- ACCESSWIRE•18 days ago
4 Biotech Stocks Making Moves On Thursday (1/31/19)
Premier Health Group (OTC:PHGRF) (CSE:PHGI), SCYNEXIS Inc (SCYX), Geron Corporation (GERN), and Fortress Biotech Inc (FBIO) represent four biotech companies creating new treatment technologies aimed to ensure that patients get the therapies best suited to their needs. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
- PR Newswire•19 days ago
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
JERSEY CITY, N.J., Jan. 30, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first interim efficacy analysis of the ongoing FURI study. FURI is a Phase 3 open-label study evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to or intolerant of currently available standards of care.
- PR Newswire•27 days ago
SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
JERSEY CITY, N.J., Jan. 22, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Armando Anido to its Board of Directors. Mr. Anido currently serves as Chairman and Chief Executive Officer of Zynerba Pharmaceuticals (ZYNE), a role he has held since October 2014.
- Simply Wall St.•28 days ago
Does SCYNEXIS, Inc.’s (NASDAQ:SCYX) CEO Salary Reflect Performance?
In 2015 Marco Taglietti was appointed CEO of SCYNEXIS, Inc. (NASDAQ:SCYX). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we Read More...
- PR Newswire•last month
Antimicrobials Working Group Announces Updates to Leadership Team
WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...
- Benzinga•last month
The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks reached 52-week highs Thursday. Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. ...
- PR Newswire•2 months ago
SCYNEXIS Provides Year-end Update and Outlines Plans for 2019
Initiated VANISH Phase 3 program of oral ibrexafungerp in acute VVC; top-line data expected in 1H 2020 with potential NDA filing in 2H 2020 Initiation of recurrent VVC Phase 3 trial planned for 1H 2019 ...
- GlobeNewswire•3 months ago
Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•3 months ago
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
JERSEY CITY, N.J. , Nov. 20, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- Zacks•3 months ago
Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of 30.00% and 6.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Scynexis: 3Q Earnings Snapshot
On a per-share basis, the Jersey City, New Jersey-based company said it had net income of 1 cent. Losses, adjusted for non-recurring gains, were 14 cents per share. The pharmaceutical company posted revenue ...
- PR Newswire•3 months ago
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
JERSEY CITY, N.J., Nov. 13, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- PR Newswire•4 months ago
SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp
JERSEY CITY, N.J., Oct. 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the successful completion of an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate, ibrexafungerp (formerly SCY-078), for patients with vulvovaginal candidiasis (VVC). The FDA has agreed with the Company's proposed overall design of the Phase 3 registration program to support approval of oral ibrexafungerp for the treatment of VVC and prevention of recurrent VVC. SCYNEXIS expects to initiate the program in the fourth quarter of 2018.
- PR Newswire•4 months ago
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
JERSEY CITY, N.J., Oct. 15, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the dosing of the first patient with a Candida auris infection, an emerging life-threatening and multidrug-resistant fungal pathogen, in a Phase 3 open-label study evaluating oral ibrexafungerp (formerly SCY-078) in patients with candidiasis caused by C. auris (the CARES Study). Ibrexafungerp, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.
- PR Newswire•5 months ago
SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week
-- HHS and CDC Lead Efforts Aim to Combat Antimicrobial Resistance, Raise Awareness of Fungal Diseases -- JERSEY CITY, N.J. , Oct. 1, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX), a biotechnology ...
- PR Newswire•5 months ago
SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018
JERSEY CITY, N.J. , Sept. 26, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- Simply Wall St.•5 months ago
Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?
A look at the shareholders of SCYNEXIS Inc (NASDAQ:SCYX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to seeRead More...
- InvestorPlace•6 months ago
5 Healthcare Stocks That Are Down, But Not Out!
Few investment sectors arouse sharply divided opinion quite like healthcare stocks. This segment features incredible volatility as poor clinical trials could devastate individual companies. During the campaign trail for the 2016 presidential election, then-real-estate-mogul Donald Trump lashed out against pharmaceuticals.
- PR Newswire•6 months ago
SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J. , Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- Zacks•6 months ago
Scynexis (SCYX) Reports Q2 Loss, Lags Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of -64.29% and -20.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 months ago
Scynexis: 2Q Earnings Snapshot
On a per-share basis, the Jersey City, New Jersey-based company said it had a loss of 23 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- PR Newswire•6 months ago
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
Oral dose regimen of ibrexafungerp (formerly SCY-078) identified for Phase 3 VVC development; Phase 3 on track for initiation in the fourth quarter of 2018 Development of ibrexafungerp intravenous (IV) ...
- ACCESSWIRE•7 months ago
Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks
Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX).
- PR Newswire•7 months ago
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
New WHO INN stem "-fungerp" signifies a novel class of antifungals Novel generic name highlights the unique attributes of SCY-078 and its potential to address significant unmet needs across multiple ...
